What is Celldex Therapeutics's D&A?

Celldex Therapeutics (CLDX) reported D&A of $854K in Q1 2026.

How has Celldex Therapeutics's D&A changed year-over-year?

Celldex Therapeutics's D&A decreased by 1.5% year-over-year, from $867K to $854K.

What is the long-term trend for Celldex Therapeutics's D&A?

Over 4 years (2021 to 2025), Celldex Therapeutics's D&A has grown at a 2.5% compound annual growth rate (CAGR), from $3.07M to $3.38M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Celldex Therapeutics CLDX D&A

D&A at other companies

PfizerPFE

$1.61B+33.2%

AbCellera Biologics Inc.ABCL

$6.84M+28.3%

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

See full

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Cash flow

See full

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

See full

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

See full

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

See full

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celldex Therapeutics's D&A?: Celldex Therapeutics (CLDX) reported D&A of $854K in Q1 2026.
How has Celldex Therapeutics's D&A changed year-over-year?: Celldex Therapeutics's D&A decreased by 1.5% year-over-year, from $867K to $854K.
What is the long-term trend for Celldex Therapeutics's D&A?: Over 4 years (2021 to 2025), Celldex Therapeutics's D&A has grown at a 2.5% compound annual growth rate (CAGR), from $3.07M to $3.38M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.